📊 NMRA Key Takeaways
Is Neumora Therapeutics, Inc. (NMRA) a Good Investment?
Neumora is a pre-revenue biotech company with severe cash burn of $206.4M annually, generating only negative profitability metrics with no offsetting revenue stream. While the company maintains adequate liquidity with $182.5M in cash, current burn rate suggests less than 1 year of runway, making the path to profitability highly uncertain and dependent on successful clinical development outcomes.
Neumora is pre-revenue with substantial operating losses (-$241M) and deeply negative returns, indicating no near-term path to profitability. Liquidity is solid (cash ~$183M; current ratio 5.9x), but burn (~-$206M OCF) suggests a short runway and dependence on external financing. Until there is tangible non-dilutive funding or revenue visibility from successful programs, fundamentals remain unfavorable.
Why Buy Neumora Therapeutics, Inc. Stock? NMRA Key Strengths
- Strong liquidity position with $182.5M in cash and 5.87x current ratio providing near-term survival capability
- Conservative leverage with 0.52x debt-to-equity ratio limiting financial distress risk
- Low capital expenditure of $16K suggests asset-light operational model typical for early-stage biotech
- Strong liquidity with $182.5M cash and 5.87x current ratio
- Minimal capex needs; spend focused on R&D
- Moderate leverage (0.52x D/E) with liabilities covered by cash
NMRA Stock Risks: Neumora Therapeutics, Inc. Investment Risks
- Severe cash burn of $206.4M annually with zero revenue indicates pre-clinical/early development stage with extended path to profitability
- Estimated cash runway of approximately 11 months at current burn rate without additional funding or revenue
- Negative ROE of -228.1% and ROA of -124.0% reflect fundamental unprofitability and value destruction from core operations
- Operating margin of -241.2M with no gross profit demonstrates inability to generate positive unit economics
- 9 Form 4 insider filings in last 90 days warrant monitoring for potential dilutive equity transactions
- No revenue; persistent large operating and net losses
- High cash burn (-$206M OCF) implying limited runway and financing risk
- Interest coverage deeply negative (-120x) and typical clinical/regulatory execution risks
Key Metrics to Watch
- Operating cash flow trend - need to see deceleration in burn rate or path to break-even
- Clinical trial progress and milestone achievements - critical for demonstrating value creation and potential revenue generation
- Cash position and runway - monitor for potential funding needs and dilutive equity raises
- Operating expense allocation - track R&D vs administrative spend efficiency as company scales
- Cash runway (months of liquidity vs burn)
- Operating cash flow (TTM)
Neumora Therapeutics, Inc. (NMRA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.87x current ratio provides a solid financial cushion.
NMRA Profit Margin, ROE & Profitability Analysis
NMRA vs Healthcare Sector: How Neumora Therapeutics, Inc. Compares
How Neumora Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Neumora Therapeutics, Inc. Stock Overvalued? NMRA Valuation Analysis 2026
Based on fundamental analysis, Neumora Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Neumora Therapeutics, Inc. Balance Sheet: NMRA Debt, Cash & Liquidity
NMRA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Neumora Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.53 indicates the company is currently unprofitable.
NMRA Revenue Growth, EPS Growth & YoY Performance
Neumora Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
NMRA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Neumora Therapeutics, Inc. (CIK: 0001885522)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NMRA
What is the AI rating for NMRA?
Neumora Therapeutics, Inc. (NMRA) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NMRA's key strengths?
Claude: Strong liquidity position with $182.5M in cash and 5.87x current ratio providing near-term survival capability. Conservative leverage with 0.52x debt-to-equity ratio limiting financial distress risk. ChatGPT: Strong liquidity with $182.5M cash and 5.87x current ratio. Minimal capex needs; spend focused on R&D.
What are the risks of investing in NMRA?
Claude: Severe cash burn of $206.4M annually with zero revenue indicates pre-clinical/early development stage with extended path to profitability. Estimated cash runway of approximately 11 months at current burn rate without additional funding or revenue. ChatGPT: No revenue; persistent large operating and net losses. High cash burn (-$206M OCF) implying limited runway and financing risk.
What is NMRA's revenue and growth?
Neumora Therapeutics, Inc. reported revenue of N/A.
Does NMRA pay dividends?
Neumora Therapeutics, Inc. does not currently pay dividends.
Where can I find NMRA SEC filings?
Official SEC filings for Neumora Therapeutics, Inc. (CIK: 0001885522) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NMRA's EPS?
Neumora Therapeutics, Inc. has a diluted EPS of $-1.45.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NMRA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Neumora Therapeutics, Inc. has a SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NMRA stock overvalued or undervalued?
Valuation metrics for NMRA: ROE of -228.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NMRA stock in 2026?
Our dual AI analysis gives Neumora Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NMRA's free cash flow?
Neumora Therapeutics, Inc.'s operating cash flow is $-206.4M, with capital expenditures of $16.0K.
How does NMRA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -228.1% (avg: 15%), current ratio 5.87 (avg: 2).